Navitoclax in Myelofibrosis: Investigational Treatment by AbbVie

AbbVie, a global research-driven biopharmaceutical company, is conducting the Phase 3 TRANSFORM-2 study to evaluate an investigational drug called Navitoclax in people with Myelofibrosis (MF). This study aims to assess the drug's safety and its impact on spleen volume when administered alongside ruxolitinib, compared to the best available therapy.

Navitoclax is an investigational drug (not yet approved) being developed for the treatment of MF. Participants in this study will be randomly selected (like picking numbers out of a hat) to be in 1 of 2 treatment arms. Neither participants nor the study doctor will be able to pick which treatment arm a participant enters. In Arm A, participants will receive navitoclax in combination with ruxolitinib. In Arm B, participants will receive the best available therapy (BAT) for MF. Adult participants with a diagnosis of MF that came back or did not get better after earlier treatment will be enrolled. Approximately 330 participants will be enrolled in approximately 210 sites across the world.

To delve into the details of the Phase 3 TRANSFORM-2 study with Navitoclax for Myelofibrosis by AbbVie, visit https://clinicaltrials.gov/study/NCT04468984?cond=Myelofibrosis%EF%BC%8CMF&term=AbbVie&rank=4